Gran Paradiso Capital Partners
QuietNew York, NYBiotechnology, Pharmaceuticals, HealthcareLast fund filed April 2014
4 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Gran Paradiso Capital Partners | April 2014 | Indefinite | $8.8M | 4 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
4 partners are named across this firm’s filings, 4 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Andrew Kimura | Quiet | None listed | 0 | 0 |
| James Healy | Quiet | Biotech & pharma, Digital health | 12 | 0 |
| Michael Marriott | Quiet | None listed | 0 | 0 |
| Rajan Godse | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of Gran Paradiso Capital Partners’s own portfolio companies, based on 12 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Gran Paradiso Capital Partners’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Capra CLO Founders | 12 | ArriVent Biopharma, Ascendis Pharma A/S, Atsena Therapeutics, BioAge Labs, Bolt Biotherapeutics, CEBIX, DXTERITY DIAGNOSTICS, HYPERION THERAPEUTICS, Iterum Therapeutics Bermuda, Iterum Therapeutics, Seaport Therapeutics, Sorbent Therapeutics |
| Sofinnova Venture Partners | 12 | ArriVent Biopharma, Ascendis Pharma A/S, Atsena Therapeutics, BioAge Labs, Bolt Biotherapeutics, CEBIX, DXTERITY DIAGNOSTICS, HYPERION THERAPEUTICS, Iterum Therapeutics Bermuda, Iterum Therapeutics, Seaport Therapeutics, Sorbent Therapeutics |
| Caduceus Capital | 2 | ArriVent Biopharma, Ascendis Pharma A/S |
| Orbimed Asia Partners | 2 | ArriVent Biopharma, Ascendis Pharma A/S |
| Orbimed Genesis | 2 | ArriVent Biopharma, Ascendis Pharma A/S |
| Vivo Innovation | 2 | Ascendis Pharma A/S, Bolt Biotherapeutics |
| Vivo Ventures VII Affiliates | 2 | Ascendis Pharma A/S, Bolt Biotherapeutics |
| Advent Life Sciences | 1 | Iterum Therapeutics Bermuda |
| ARCH Venture Partners | 1 | Seaport Therapeutics |
| Hatteras Venture Partners | 1 | Atsena Therapeutics |
| Longitude 103.8 East | 1 | BioAge Labs |
| Longitude Capital | 1 | BioAge Labs |
| Longitude Prime | 1 | BioAge Labs |
| New Leaf | 1 | Iterum Therapeutics Bermuda |
| Pivotal bioVenture Partners | 1 | Bolt Biotherapeutics |
A shared board seat: a company where filings name a Gran Paradiso Capital Partners partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.